Diagnostic Imaging’s Weekly Scan: May 31 — June 6

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

In a recent episode of our “Molecular Imaging in Focus” series, Phillip Kuo, MD, discussed new comparative multicenter prospective research, presented at the SNMMI conference, examining the urinary radioactivity of two PSMA PET radiotracers Posluma and Pylarify.

Noting the potential for workload efficiencies in interpreting screening digital breast tomosynthesis (DBT) images, the authors of a new study in Radiology found the use of slab reconstruction technology improved specificity without any impact on sensitivity or cancer detection rate.

In another episode of our “Molecular Imaging in Focus” series, Isabelle Boileau, PhD, discussed preliminary research, presented at the SNMMI conference, which suggests the utility of a novel tau PET imaging agent that may help detect chronic traumatic encephalopathy (CTE) in living patients.

There were some intriguing findings reported in the New England Journal of Medicine when PSMA PET was added to the protocol for a multinational phase 3 trial of perioperative apalutamide for high-risk localized or locally advanced prostate cancer. While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.

In another interview with Diagnostic Imaging, Alicia Corlett, a nuclear medicine technologist, discussed new research showing that a total body PET/CT imaging platform with a long axis field of view detected more lesions in 68 percent of patients while reducing scan times by 83 percent in comparison to short-axial field of view PET/CT scanners.